Weight-Loss Drugs May Help Sleep Apnea and Arthritis

New FDA-approved GLP-1 drug Foundayo, still primarily marketed for weight loss, has shown promise in reducing obstructive sleep apnea episodes in obese individuals. In clinical trials, study participants who took Foundayo experienced an average loss of 28 pounds, corresponding to 11% of their initial body weight, compared to placebo.

Notably, those on the drug also reported a 44% decrease in overnight apnea events over a year, placing Foundayo on par with Zepbound for sleep apnea treatment. Additionally, Foundayo's effects extend to easing knee pain caused by osteoarthritis, with injectable retatrutide demonstrating a 50% reduction in knee pain and significant weight loss in obese patients with the condition.

Researchers suggest that GLP-1 drugs like Foundayo and retatrutide may contribute to pain relief through anti-inflammatory mechanisms, in addition to weight loss effects.